SS-31 Research: What Elamipretide Human Trials Actually Found

SS-31, also known as elamipretide, is discussed in mitochondrial research because of its interaction with cardiolipin in mitochondrial membranes. However, a plausible biological target does not tell us whether a person will walk farther, feel less fatigued or gain muscle strength. Those questions require human studies with defined outcomes. The elamipretide programme provides a useful example of why both positive signals and negative trials belong in an evidence summary. [1–3]

The early crossover trial: signals worth testing

A randomised crossover study published in 2020 examined adults with primary mitochondrial myopathy. Participants received short treatment periods with elamipretide and placebo, allowing comparisons within individuals. The six-minute walking-distance result did not achieve statistical significance for the primary endpoint. Some secondary patient-reported fatigue and symptom measures favoured elamipretide. Injection-site reactions were common. [1]

A crossover design can reduce some variation between participants, but it also requires attention to treatment order and effects that might persist between periods. More importantly, a favourable secondary measure cannot replace an unsuccessful primary endpoint. This study supplied a reason to investigate further, rather than a definitive answer about functional benefit.

MMPOWER-3: the larger trial did not meet its primary endpoints

The phase 3 MMPOWER-3 trial randomised 218 participants with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks. Its primary outcomes were six-minute walking distance and a disease-specific total fatigue score. Neither showed a statistically significant treatment benefit. The between-group walking-distance estimate was minus 3.2 metres, with a confidence interval spanning both worse and better outcomes. [2]

The investigators described treatment as generally well tolerated, with most adverse events mild or moderate. Tolerability and efficacy are different conclusions: tolerating an intervention does not establish that it improves the condition being studied. Equally, a negative trial in this population should not be stretched into a claim about every possible mitochondrial disorder.

How the Barth syndrome approval fits

In September 2025, the US FDA granted accelerated approval to Forzinity, an elamipretide medicine, for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg. The FDA trial snapshot describes a 12-patient crossover trial and its long open-label extension. This is a specific disease, product and indication. [3, 4]

That regulatory decision does not convert the negative MMPOWER-3 results into positive ones. It also does not establish an anti-ageing effect, an improvement in ordinary exercise performance or equivalence between an approved medicine and a laboratory vial labelled SS-31. Different diagnoses and endpoints can lead to different conclusions without either study being ignored.

Reading mitochondrial research without overgeneralising

For any SS-31 claim, ask which population was studied, whether the endpoint was specified in advance and whether the result came from a controlled comparison. A cellular energy marker, a patient-reported symptom and a functional test answer different questions. Open-label follow-up can provide useful observations, but it does not retain the same protection against bias as a blinded placebo comparison.

The most defensible interpretation is indication-specific: promising mechanisms justify experiments, while clinical claims must follow the actual trial results. This selected-study overview was prepared on 22 October 2026. Bali Peptide Lab sells research materials and has a commercial interest in this topic. Its catalogue materials are not substitutes for approved medicines, and this article provides no personal-use or dosing guidance.